Why Is Cancer Player Candel Therapeutics Stock Trading Higher Today?
Portfolio Pulse from Vandana Singh
Candel Therapeutics Inc (NASDAQ:CADL) released initial interim survival and immunological biomarker data from the ongoing phase 2 trial of CAN-2409 plus valacyclovir for pancreatic ductal adenocarcinoma (PDAC). The data showed a survival rate of 71.4% at both 24 and 36 months in patients who received the CAN-2409 regimen, versus only 16.7% in patients with standard of care chemoradiation. The company's shares are up 20.86% at $0.82.
November 06, 2023 | 6:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Candel Therapeutics' phase 2 trial data shows promising survival rates, leading to a 20.86% increase in share price.
The positive interim data from the phase 2 trial of CAN-2409 indicates a potential breakthrough in the treatment of PDAC, which has led to increased investor confidence and a surge in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100